The Chinese University of Hong Kong Jockey Club Centre for Osteoporosis Care and Control
Hong Kong
NCT Number: NCT04709393
Hip fragility fractures are a major threat to functional independence in older adults locally and globally. In Hong Kong, the prevalence of osteoporosis and osteopenia in people aged >50 years were reported to be as high as 37% and 52%, respectively. The major challenge in fragility fracture prevention is that fragility fracture is caused by the combination of osteoporosis and propensity to fall, and both of these conditions are multifactorial. Ample evidence shows that fall risks can be reduced by well-designed exercises, and osteoporosis can be effectively diagnosed by Dual-energy X-ray Absorptiometry imaging (DXA) and treated with anti-osteoporosis medication. Lifestyle modifications e.g. diet, optimal physical activity, environmental safety can also help to prevent falls or improve bone health. The brief Fracture Risk Assessment Tool (FRAX) and SARC-F provide a low cost of prescreening for fracture risk and sarcopenia, respectively. Using SARC-F in conjunction with FRAX has increased sensitivity for hip fracture risk prediction. FRAX+SARC-F may help increase the public awareness of osteoporosis and get the at-risk group to receive diagnostic tests and be treated. This model should fit in well with the coming District Health Centres across Hong Kong.
This study is active but is not currently recruiting participants.
Notify Me65 year and older
All sexes
Interventional
Not applicable
Hong Kong
Participants will be randomly assigned to either the pre-screening or control group in a 1:1 ratio. Independent personnel not involved in data collection or intervention will perform and conceal the randomization using an online data server. Research assistants who are blinded to the group allocation will conduct all the baseline assessments and subsequent event surveillance. All data will also be entered and checked by the blinded research assistants. All procedures concur with the Declaration of Helsinki (2013).
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Pre-screening group participants will receive the FRAX+SARC-F questionnaire pre-screening and be notified of the preliminary estimation of their future hip fracture risk before being invited to our DXA screening and fall-risk assessment.
Time frame: within 1-6 months
proportions of participants diagnosed with osteoporosis in the FRAX+SARC-F pre-screening and control groups.
Time frame: 6-12 months
Number of participants receiving osteoporosis screening in the arms
Time frame: 6-12 months
Number of participants receiving fall risk assessment in the arms
Time frame: 6-12 months
Number of participants receiving anti-osteoporosis intervention in the arms
Time frame: 6-12 months
Number of participants receiving fall prevention intervention in the arms
Time frame: 12 months
Number of participants having subsequent fall in the arms
Time frame: 12 months
Number of participants having subsequent fracture in the arms
Chinese University of Hong Kong
Other
The Effects of FRAX+SARC-F Questionnaire Pre-screening on Promoting Public Awareness of Fragility Fracture and Fall Prevention Among Community-dwelling Older Adults
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03512262
Age Related Osteoporosis, Bone Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT04093856
Body Weight, Bone Diseases
Montreal, Quebec, Canada
View Trial DetailsNCT07154719
Body Weight, Bone Diseases
Baton Rouge, Louisiana, United States
View Trial DetailsNCT04947722
Bone Diseases, Bone Diseases, Metabolic
Hamilton, Ontario, Canada
View Trial Details